Latest filing published 12 Aug 2022 for ARTELO BIOSCIENCES, INC., €4,653.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 11 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -55.5%Entry US$706.32 · Close at T+365 US$314.28
- -48.8%Entry US$613.98 · Close at T+365 US$314.28
- -67.9%Entry US$2,843.10 · Close at T+365 US$911.25
- +1.7%Entry US$2,891.70 · Close at T+365 US$2,940.30
- -1.5%Entry US$3,207.60 · Close at T+365 US$3,159.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gregory D. Gorgas: trading record in brief
All filings by Gregory D. Gorgas on record concern Artelo Biosciences, Inc. We count 11 filings; the first trade dates from 11 October 2019 and the latest from 12 August 2022.
On the market, this insider has only ever bought: 11 purchases, €55k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2022 alone, the filings show 2 purchases and no sales.
The median purchase comes to €4,703. Of 11 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 11 purchases show a median change of -9.8%, with the price up in 18% of them. This is a record of the past, not a forecast.
The latest filing, published on 12 August 2022, reports an open-market purchase of €4,653 in Artelo Biosciences, Inc. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Gregory D. Gorgas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,200 shares@ US$4.008.4% of flowCommon StockSEC:0001640334-22-001760:0Canonical exit: 10 Nov 2022 (T+90)
- 1,200 shares@ US$4.038.5% of flowCommon StockSEC:0001640334-22-001706:0Canonical exit: 9 Nov 2022 (T+90)
- 8,500 shares@ US$1.1517.8% of flowCommon StockSEC:0001640334-21-000982:0Canonical exit: 15 Jul 2021 (T+90)
- 4,200 shares@ US$1.2112.4% of flowCommon StockSEC:0001640334-20-001281:0Canonical exit: 13 Aug 2020 (T+90)
- 4,167 shares@ US$1.2012.1% of flowCommon StockSEC:0001640334-20-001028:0Canonical exit: 2 Aug 2020 (T+90)
- 2,400 shares@ US$2.2112.6% of flowCommon StockSEC:0001640334-19-002181:0Canonical exit: 2 Feb 2020 (T+90)
- 2,600 shares@ US$1.9912.3% of flowCommon StockSEC:0001640334-19-002169:0Canonical exit: 28 Jan 2020 (T+90)
- 2,500 shares@ US$1.9511.6% of flowCommon StockSEC:0001640334-19-002169:1Canonical exit: 29 Jan 2020 (T+90)
- 2,500 shares@ US$2.2813.5% of flowCommon StockSEC:0001640334-19-002169:2Canonical exit: 30 Jan 2020 (T+90)
- 2,600 shares@ US$2.0512.8% of flowCommon StockSEC:0001640334-19-002067:0Canonical exit: 13 Jan 2020 (T+90)
- 2,700 shares@ US$1.9612.7% of flowCommon StockSEC:0001640334-19-002035:0Canonical exit: 9 Jan 2020 (T+90)
11 of 11 declarations